Intellia Therapeutics Inc (NASDAQ:NTLA) saw an uptick in trading volume on Tuesday . 2,294,100 shares traded hands during mid-day trading, an increase of 305% from the previous session’s volume of 566,316 shares.The stock last traded at $14.98 and had previously closed at $13.60.

Several research firms have issued reports on NTLA. BidaskClub upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. Chardan Capital set a $57.50 price target on Intellia Therapeutics and gave the stock a “buy” rating in a report on Friday, September 27th. ValuEngine downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 5th. Zacks Investment Research raised Intellia Therapeutics from a “hold” rating to a “strong-buy” rating and set a $15.00 price target for the company in a report on Wednesday, November 6th. Finally, Raymond James raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $24.94.

The company has a debt-to-equity ratio of 0.05, a current ratio of 7.89 and a quick ratio of 7.89. The firm has a market cap of $650.13 million, a price-to-earnings ratio of -7.64 and a beta of 2.68. The firm has a fifty day simple moving average of $12.24 and a two-hundred day simple moving average of $14.72.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.12. The business had revenue of $10.60 million during the quarter, compared to the consensus estimate of $9.17 million. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company’s quarterly revenue was up 43.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.53) earnings per share. Equities analysts anticipate that Intellia Therapeutics Inc will post -2.09 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in NTLA. Benjamin Edwards Inc. lifted its holdings in shares of Intellia Therapeutics by 60.9% during the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after purchasing an additional 640 shares during the period. Bank of Montreal Can lifted its holdings in shares of Intellia Therapeutics by 406.5% during the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after purchasing an additional 3,069 shares during the period. Mizuho Securities Co. Ltd. acquired a new stake in shares of Intellia Therapeutics during the second quarter worth about $64,000. Aperio Group LLC acquired a new stake in shares of Intellia Therapeutics during the second quarter worth about $83,000. Finally, Resources Investment Advisors LLC. lifted its holdings in shares of Intellia Therapeutics by 60.2% during the second quarter. Resources Investment Advisors LLC. now owns 8,648 shares of the company’s stock worth $142,000 after purchasing an additional 3,250 shares during the period. 95.46% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.